Alirocumab, sold under the brand name Praluent, is a medication used as a second-line treatment for high cholesterol for adults whose cholesterol is not...
24 KB (2,254 words) - 05:22, 7 April 2024
Regeneron's drug alirocumab infringed Amgen's patents; Amgen then requested an injunction barring Regeneron and Sanofi from marketing alirocumab, which was...
17 KB (1,472 words) - 06:49, 29 June 2024
can lower LDL particle concentrations. The first two PCSK9 inhibitors, alirocumab and evolocumab, were approved as once every two week injections, by the...
69 KB (7,354 words) - 16:56, 11 June 2024
metastatic colorectal cancer approved by the FDA in August 2012. Praluent (alirocumab) is indicated as an adjunct to diet and maximally tolerated statin therapy...
26 KB (2,282 words) - 07:41, 31 August 2024
Injectable antibodies against the protein PCSK9 (evolocumab, bococizumab, alirocumab) can reduce LDL cholesterol and have been shown to reduce mortality. In...
61 KB (6,215 words) - 17:45, 31 May 2024
2024 MA 2001 Valdecoxib 2016 N/A SM 2001 Etoricoxib 2016 N/A SM 2003 Alirocumab 2015 2035 MA 2006 Linagliptin 2011 2031 SM 2007 Apixaban 2012 2032 SM...
34 KB (2,388 words) - 06:34, 15 August 2024
(Clopidogrel), for atherothrombosis, marketed by Bristol-Myers Squibb. Praluent (Alirocumab), for heterozygous familial hypercholesterolemia and clinical atherosclerotic...
91 KB (8,778 words) - 06:05, 10 August 2024
Alemtuzumab Lemtrada, Campath mab humanized CD52 Y multiple sclerosis Alirocumab Praluent mab human PCSK9 Y hypercholesterolemia Altumomab pentetate Hybri-ceaker...
136 KB (4,020 words) - 07:14, 15 August 2024
importance of early identification of FH and treatment with statins. Alirocumab and evolocumab, both monoclonal antibodies against PCSK9, are specifically...
48 KB (5,456 words) - 18:52, 29 May 2024
intravenous humanized CD52 B-cell chronic lymphocytic leukemia 103948 Link alirocumab Praluent Sanofi Aventis 7/24/2015 subcutaneous fully human PCSK9 Heterozygous...
57 KB (4,072 words) - 11:12, 5 August 2024